Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat TIW for Anemia in Dialysis-Dependent CKD
NCT03242967Phase 3Withdrawn
- Sponsor
- Akebia Therapeutics
- Start
- Aug 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Akebia Therapeutics. Primary endpoint: Mean change in Hb between baseline and the primary evaluation period at Week 36. Planned start Aug 2017; status: withdrawn.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03242967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242967.